Hege Sagstuen Haugnes
Papers
4
Total Citations
32
H-Index
3
About
Hege Sagstuen Haugnes is a clinical researcher whose work centers on urological oncology, with a particular focus on testicular cancer management and prostate cancer treatment outcomes. She is a prominent contributor to the Swedish Norwegian Testicular Cancer Group (SWENOTECA), a collaborative research consortium driving innovative approaches to seminoma treatment. Her most impactful work investigates retroperitoneal lymph node dissection (RPLND) as a primary surgical alternative to conventional chemotherapy and radiotherapy for low-volume metastatic seminoma — treatments historically associated with significant long-term toxicities including secondary malignancies and cardiovascular complications. By demonstrating the oncological efficacy and surgical safety of RPLND in population-based cohorts, Haugnes and her colleagues are actively reshaping treatment paradigms for stage IIA–IIC seminoma patients. Her most-cited paper (2024, 19 citations) represents a landmark contribution to this evolving field. Beyond testicular cancer, she has also examined patient-reported outcomes following curative prostate cancer treatments, including prostatectomy and radiotherapy, contributing important real-world evidence on quality-of-life considerations. Her research collectively prioritizes minimizing treatment burden while maintaining excellent survival outcomes, making her work highly relevant to patients and oncologists navigating modern urological cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4